• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分化型甲状腺癌患者接受¹³¹I治疗时的外照射剂量率及体内滞留活度研究。

The study of external dose rate and retained body activity of patients receiving 131I therapy for differentiated thyroid carcinoma.

作者信息

Zhang Haiying, Jiao Ling, Cui Songye, Wang Liang, Tan Jian, Zhang Guizhi, He Yajing, Ruan Shuzhou, Fan Saijun, Zhang Wenyi

机构信息

Tianjin Key Laboratory of Molecular Nuclear Medicine, Institute Of Radiation Medicine, Chinese Academy Of Medical Sciences & Peking Union Medical College, Tianjin 300192, China.

Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China.

出版信息

Int J Environ Res Public Health. 2014 Oct 21;11(10):10991-1003. doi: 10.3390/ijerph111010991.

DOI:10.3390/ijerph111010991
PMID:25337944
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4211018/
Abstract

Radiation safety is an integral part of targeted radionuclide therapy. The aim of this work was to study the external dose rate and retained body activity as functions of time in differentiated thyroid carcinoma patients receiving 131I therapy. Seventy patients were stratified into two groups: the ablation group (A) and the follow-up group (FU). The patients' external dose rate was measured, and simultaneously, their retained body radiation activity was monitored at various time points. The equations of the external dose rate and the retained body activity, described as a function of hours post administration, were fitted. Additionally, the release time for patients was calculated. The reduction in activity in the group receiving a second or subsequent treatment was more rapid than the group receiving only the initial treatment. Most important, an expeditious method was established to indirectly evaluate the retained body activity of patients by measuring the external dose rate with a portable radiation survey meter. By this method, the calculated external dose rate limits are 19.2, 8.85, 5.08 and 2.32 μSv·h-1 at 1, 1.5, 2 and 3 m, respectively, according to a patient's released threshold level of retained body activity <400 MBq. This study is beneficial for radiation safety decision-making.

摘要

辐射安全是靶向放射性核素治疗不可或缺的一部分。本研究的目的是研究接受¹³¹I治疗的分化型甲状腺癌患者的外照射剂量率和体内滞留活度随时间的变化情况。70例患者被分为两组:消融组(A)和随访组(FU)。测量患者的外照射剂量率,同时在不同时间点监测其体内滞留的辐射活度。拟合了外照射剂量率和体内滞留活度随给药后小时数变化的方程。此外,还计算了患者的出院时间。接受第二次或后续治疗的组中活度的降低比仅接受初始治疗的组更快。最重要的是,建立了一种快速方法,通过使用便携式辐射检测仪测量外照射剂量率来间接评估患者体内的滞留活度。根据患者体内滞留活度<400MBq的出院阈值水平,通过该方法计算出在距离患者1、1.5、2和3米处的外照射剂量率限值分别为19.2、8.85、5.08和2.32μSv·h⁻¹。本研究有助于辐射安全决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca04/4211018/6025626b306c/ijerph-11-10991-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca04/4211018/3b42edd2e974/ijerph-11-10991-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca04/4211018/ad8d61caa905/ijerph-11-10991-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca04/4211018/56dbdcf9e2e3/ijerph-11-10991-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca04/4211018/6025626b306c/ijerph-11-10991-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca04/4211018/3b42edd2e974/ijerph-11-10991-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca04/4211018/ad8d61caa905/ijerph-11-10991-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca04/4211018/56dbdcf9e2e3/ijerph-11-10991-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca04/4211018/6025626b306c/ijerph-11-10991-g004.jpg

相似文献

1
The study of external dose rate and retained body activity of patients receiving 131I therapy for differentiated thyroid carcinoma.分化型甲状腺癌患者接受¹³¹I治疗时的外照射剂量率及体内滞留活度研究。
Int J Environ Res Public Health. 2014 Oct 21;11(10):10991-1003. doi: 10.3390/ijerph111010991.
2
Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid.接受碘-131治疗甲状腺癌患者的辐射剂量率。
Eur J Nucl Med. 1996 Feb;23(2):123-30. doi: 10.1007/BF01731834.
3
Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements.甲状腺癌:基于实际生物动力学测量的 131I 治疗中的辐射安全预防措施。
Radiology. 2014 Oct;273(1):211-9. doi: 10.1148/radiol.14132234. Epub 2014 Jun 5.
4
A retrospective study on the transition of radiation dose rate and iodine distribution in patients with I-131-treated well-differentiated thyroid cancer to improve bed control shorten isolation periods.一项关于接受 I-131 治疗的分化型甲状腺癌患者辐射剂量率和碘分布转变的回顾性研究,以改善床位控制并缩短隔离期。
Ann Nucl Med. 2012 Jun;26(5):390-6. doi: 10.1007/s12149-012-0586-3. Epub 2012 Mar 3.
5
A practical individualized radiation precaution based on the dose rate at release time after inpatient 131I ablation therapy.基于住院患者 131I 消融治疗后释放时间的剂量率的实用个体化辐射防护。
PLoS One. 2021 May 21;16(5):e0251627. doi: 10.1371/journal.pone.0251627. eCollection 2021.
6
Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.重组人促甲状腺激素后给予高活度¹³¹I治疗转移性分化型甲状腺癌的骨髓剂量测定及安全性
J Nucl Med. 2004 Sep;45(9):1549-54.
7
Thyroid remnant ablation using 1,110 MBq of I-131 after total thyroidectomy: regulatory considerations on release of patients after unsealed radioiodine therapy.甲状腺全切术后使用 1,110MBq 的 I-131 进行残余甲状腺消融: unsealed radioiodine therapy 后患者出院的监管考虑因素。
Ann Nucl Med. 2012 May;26(4):370-8. doi: 10.1007/s12149-012-0590-7. Epub 2012 Mar 27.
8
Hospital discharge of patients with thyroid carcinoma treated with 131I.接受¹³¹I治疗的甲状腺癌患者出院情况。
J Nucl Med. 2002 Jan;43(1):61-5.
9
Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer: Study of External Dose Rate Attenuation Law and Individualized Patient Management.放射性碘治疗分化型甲状腺癌患者:外部剂量率衰减规律与个体化患者管理研究。
Thyroid. 2019 Jan;29(1):93-100. doi: 10.1089/thy.2017.0570. Epub 2018 Dec 31.
10
Radiation doses to cohabitants of patients undergoing radioiodine ablation for thyroid cancer: poor compliance with radiation protection guidelines but low radiation exposure.接受放射性碘消融治疗的甲状腺癌患者的同居者所受辐射剂量:对辐射防护指南的依从性差但辐射暴露量低。
Nucl Med Commun. 2011 Sep;32(9):829-33. doi: 10.1097/MNM.0b013e328347f1c2.

引用本文的文献

1
Radiation Safety and External Radiation Exposure Rate of Patients Receiving I-131 Therapy for Hyperthyroidism and Remnant Ablation as Outpatient: An Institutional Experience.门诊接受 I-131 治疗甲亢及残留甲状腺组织消融患者的辐射安全与外照射剂量率:一项机构经验
World J Nucl Med. 2023 Sep 6;22(3):203-207. doi: 10.1055/s-0043-1771285. eCollection 2023 Sep.
2
A real-time system to report abnormal events involving staff in a nuclear medicine therapy unit.实时系统,用于报告核医学治疗单位中涉及员工的异常事件。
Radiat Prot Dosimetry. 2023 May 24;199(8-9):962-969. doi: 10.1093/rpd/ncad098.

本文引用的文献

1
Estimating radiation absorbed dose of individuals nearby 131I-treated hyperthyroid patients.估算接受 131I 治疗的甲状腺功能亢进症患者附近个体的辐射吸收剂量。
Health Phys. 2014 Mar;106(3):365-9. doi: 10.1097/HP.0b013e3182a1c8d5.
2
Radiation protection procedures in 131I treatments for thyroid cancer in patients requiring hemodialysis.接受血液透析的甲状腺癌患者¹³¹I治疗中的辐射防护程序
Nucl Med Commun. 2014 Jun;35(6):626-30. doi: 10.1097/MNM.0000000000000095.
3
Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52.
用黑色素结合苯酰胺 131I-BA52 对转移性黑色素瘤患者进行放射性药物治疗。
J Nucl Med. 2014 Jan;55(1):9-14. doi: 10.2967/jnumed.112.112789. Epub 2013 Nov 25.
4
The evaluation of urine activity and external dose rate from patients receiving radioiodine therapy for thyroid cancer.对接受甲状腺癌放射性碘治疗患者的尿液活性和外照射剂量率的评估。
Radiat Prot Dosimetry. 2013;156(1):25-9. doi: 10.1093/rpd/nct036. Epub 2013 Mar 27.
5
Assessment of radioiodine clearance in patients with differentiated thyroid cancer.分化型甲状腺癌患者放射性碘清除率的评估。
Radiat Prot Dosimetry. 2012 Dec;152(4):323-7. doi: 10.1093/rpd/ncs063. Epub 2012 May 4.
6
Targeted radio-nuclide therapy of skeletal metastases.骨转移的靶向放射性核素治疗。
Cancer Treat Rev. 2013 Feb;39(1):18-26. doi: 10.1016/j.ctrv.2012.03.006. Epub 2012 Apr 24.
7
Outpatient therapeutic nuclear oncology.门诊治疗核医学。
Ann Nucl Med. 2012 May;26(4):289-97. doi: 10.1007/s12149-011-0566-z. Epub 2012 Jan 7.
8
131I activity in urine to the sewer system due to thyroidal treatments.由于甲状腺治疗,尿液中的 131I 活性排入下水道系统。
Health Phys. 2011 Aug;101 Suppl 2:S110-5. doi: 10.1097/HP.0b013e318209459c.
9
Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association.131I 放射性碘治疗甲状腺疾病患者的辐射安全:美国甲状腺协会的实践建议。
Thyroid. 2011 Apr;21(4):335-46. doi: 10.1089/thy.2010.0403. Epub 2011 Mar 18.
10
Salivary gland protection with sialagogues: a case study.使用催涎剂保护唾液腺:一项病例研究。
Thyroid. 2009 Sep;19(9):1005-8. doi: 10.1089/thy.2008.0381.